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Abstract
Carbohydrate transporters or GLUTs of the major facilitator superfamily
(MFS) are responsible for transporting sugars into the cell and have been of
research interest for decades. Disruptions, mutations, and over-activations of GLUTs
have been linked to a number of major diseases including cancer, obesity, and
diabetes. Differentiating between transporters is incredibly difficult due to highly
conserved structures, and so specific targeting between transporters has proven a
complex challenge. GLUTs are highly flexible in their conformations however exactly
what will and will not pass through the transporter is ambiguous at best, and many
attempt to target these transporters have failed.
In an attempt to further understand GLUT5’s transport capacity and specificity
several probes were created by conjugating 1-amino-2,5-anhydro-D-mannitol with a
number of fluorescent coumarins. These probes were then tested in cancer and
normal breast cell lines to determine uptake mechanisms and transport specificity.
To determine transport specificity probes were tested in the presence of competitive
and non-competitive inhibitors. Probe analysis was carried out by evaluating the
gained fluorescence of treated cells in a microplate setting and through confocal
microscopy. Confocal imaging and Z-stack was utilized to understand the ability of
the probe to pass into the cytosol or to remain in the cellular membrane. As a result,
probes reflecting uptake capacity vs. membrane expression of the transporter were
developed. The cumulative analysis of structure-uptake relationship for the
developed probes gives insight into the capability of GLUT5 cargo transport and as
well as a method for imaging GLUT5 in the cellular membrane.
xi

Chapter 1
Introduction
1.1 GLUTs: classification and expression
GLUTs (facilitative glucose transporters) are expressed throughout the body and
are vital for survival of cells. Gluts mediate a gradient dependent transport of
carbohydrates into and out of the cell but cannot export their substrate’s
phosphorylated counterparts [1, 2]. There are fourteen known GLUTs and based on
sequence, structural and substrate similarities are split into three major classes:
Class I, II and III. Class I GLUTs (1-4 and 14) primarily facilitate uptake of glucose,
but some are responsible for various other hexoses (Table 1). Class II GLUTs (5, 7,
9 and 11) are primarily fructose transporters, and Class III GLUTs (6, 8, 10, 12, and
13 (HMIT1)) are structurally atypical members of the GLUT family.
GLUT2-4 are relatively localized in specific areas. GLUT2 is mainly located in the
liver and gastrointestinal tract. GLUT3 is primarily located in neuron cells and mainly
transports glucose. GLUT4 is the unique of the class I transporters as it mainly
reside inside the cell and is only brought to the surface in the presence of insulin. In
low insulin concentrations, it resides in intracellular vesicles inside the cell membrane
and is predominately present in skeletal and cardiac muscles [25]. GLUT4 has been
found to have links with insulin resistance and diabetes and has been a potential
therapeutic target [26].
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Table 1. Glut Transporters
Class

Class I

Transporter

Expression in Normal Cells

Substrate

Glut1

erythrocytes

glucose,
galactose

Glut2

renal tubular, intestinal
epithelial, liver and
pancreatic β cells

glucose,
galactose,
fructose,
glucosamine

Glut3

neurons and placenta

glucose,
galactose,
mannose

Glut4

adipose tissue and striated
muscle

Glut14

testis

Glut5

intestinal epithelial,
erythrocytes, sperm

Glut7

apical membrane in small
and large intestine

glucose, fructose

Glut9

liver, kidney and intestine

glucose, fructose

Glut11

muscle, heart, fat, placenta,
kidney, and pancreas

glucose, fructose

Glut 6

renal tubular, intestinal
epithelial, liver and
pancreatic β cells

Glut 8

testis, brain, fat, liver, and
spleen

Glut 10

heart and lung

glucose,
galactose

Glut 12

insulin-sensitive tissues

glucose,
galactose,
fructose

Glut 13

Brain

myoinositol

Class II

Class III

2

glucose,
galactose,
mannose, xylose
glucose,
galactose
fructose

glucose
glucose, fructose

1.2 GLUTs: Structure and Mechanism of Function
GLUT structures are highly conserved and are typically two bundles of six
transmembrane helixes (TM) with four to five intercellular helixes (IC) for stabilization
[16, 17]. GLUTs rely on a concentration gradient to transport substrates; it is based on
substrates moving from an area of high concentration (typically outside the cell) into
an area of low concentration (typically inside the cell). Transportation begins with
outward-open conformation of GLUTs, and a substrate binds substrate active site.
Once key residues have been bound, interactions between TMs trigger a
conformational change within the transporter that orients the substrate to the
endofacial binding site. Once deposited into the cell, the substrate can be effectively
excreted via the same pathway. However, in the conditions of sufficient carbohydrate
phosphorylation, carbohydrate excretion is believed to play an insignificant role in
evaluating the kinetics of the uptake [18-20], because GLUT transporters being
antiporter take up and excrete carbohydrates, but not their phosphorylated analogs
[21]. As a result, sugar transport is loosely coupled to phosphorylation, so that a high
rate of sugar accumulation is maintained without requiring a reduction in the
intracellular sugar concentration.
1.2.1

Class I: GLUTs 1-4

GLUT1 is the most widely studied and targeted of the GLUT transporters and is
currently the key target in Positron Emission Topography (PET) imaging using a F18labelled glucose and is widely used throughout the world as a potent cancer imaging
agent. GLUT1 has twelve transmembrane (TM) segments split into two six-helix
bundles carboxy- and amino- domains (C and N respectfully). The transporter
3

preferentially sits in an exofacial conformation stabilized by inter-TM salt bridges on
the endofacial side of the transporter that are not present in the endofacial-open
conformation of the transporter. When glucose enters the binding site increased
interactions between C and N domains and with a protonation of Asp126 leads to
cation-π interaction with the aromatic Tyr292 residue causes the transporter to adopt
the intercellular conformation. With the release of the substrate via concentration
gradient interactions between C and N residues equilibrate and with a deprotonation
returns to the original extracellular state [16].
Central cavity of GLUT1 encompasses a multitude of residues including
Phe26, Gln166, Ile169, Ile173, Gln287, Gln288, Asn324, Phe379, Gly384, Trp388,
Asn411, and Trp419, with most of these residues residing on the C-terminal of the
protein leading to asymmetrical binding site [17]. Understanding what is necessary for
binding and what can be tolerated to initiate transport is vital for designing anything
from probes to cytotoxic therapies for GLUT1. To determine the vital interactions, a
large series of structural activity relationship (SAR) studies have been conducted.
Early studies have shown that GLUT1 has a highly effective in transporting D-glucose
while struggles to transport L-glucose, suggesting the transport to be sensitive towards
stereochemistry of the glucose hydroxyls [22]. In agreement with these observations,
glucose anomers have shown a loss in the uptake efficiency. Poor uptake was also
documented for glucose analogs bearing alkoxy groups. Contrary to effects observed
by removal of the C2 and C9 hydroxyls which did not impact the uptake of glucose,
with resulting 2-deoxy and 6-deoxy-D-glucose competing for uptake with D-glucose
[23]. Building upon these findings 2-chloro and 2,2’-dichlor-2-deoxy-D-glucose were

4

found to have similar binding affinity to D-glucose, suggesting C2 position may serve
Table 2. Structure-Uptake relationship of GLUT uptake
Substrate

Glut1a

Transport Rate, (%)
Glut2b
Glut3b

Glut4b

Controls
D-glucose

1

20±6

10±2

12±3

L-glucose

95

100

100

100

82

109±10

104±12

79±12

2-Deoxy-D-glucose

1

20±2

12±2

14±9

D-Mannose

33

29±3

14±2

13±7

2-Chloro-D-glucose

n.d.

76±5

42±3

40±7

3-O-Methyl-D-glucose

30

73±6

17±3

41±7

3-O-Propyl-D-glucose

n.d.

100±12

80±7

72±8

3-Deoxy-D-glucose

67

103±12

85±7

106±12

3-Bromo-D-glucose

n.d.

95±10

75±4

79±12

85±5

14±2

40±6

75

59±6

96±7

96±7

48

110±12

57±5

96±12

8

33±9

46±7

44±7

D-Xylose

n.d.

106±9

78±6

75±6

L-Arabinose

n.d.

138±22

63±7

90±8

6-O-Methyl-D-galactose

95

57±10

6-Fluoro-D-galactose

n.d.

C1 Analogs
1-Deoxy-D-glucose
C2 Analogs

C3 Analogs

3-Fluoro-D-glucose
D-Allose
C4 Analogs
D-Galactose
C5/C6 Analogs
6-Deoxy-D-glucose

50±12

Transport rate determined relative to the uptake of

30±9

59±6
48±12

aD-[3H]-glucose; b[2,6-3H]-2-deoxyglucose;n.d.,

not determined.

as an accommodating position for payload conjugation.
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109±11

Continues testing has revealed that glucose recognition is highly dependent on
the C1-OH as an H-bonding acceptor and the binding has been suggested to work in
tandem with hydrophobic interactions on the C6 position. C1 methylation, removal or
substitution (with exception of 1-fluoro-D-glucose) all demonstrated exceptional loss
of uptake [9, 23, 24]. Although removing C6 hydroxyl still permitted glucose transport,
any significant bulk on the position reduced transporter affinity. Overall SAR studies
have identified C1, C3 and C4 hydroxyls and C6 hydrophobic interactions are critical
points for glucose binding to the active site in GLUT1.
GLUT2, 3 and 4 share many key H-bonding interactions when transporting
glucose as GLUT2 and 3 require the presence of C1, C3 and C4 hydroxyls for effective
glucose transport [11]. Like with GLUT1 C2 substitution was tolerated but did
negatively impact uptake with GLUT2 being the most sensitive to this alteration.
GLUTs 2-4, unlike GLUT1, are not glucose specific and have been found to transport
D-mannose as efficiently as D-glucose. GLUT1 and 3 can effectively transport 3fluoro-D-glucose but GLUT2 being unable, pointing towards a C3-OH H-donating
effect not required in GLUT3 or 4 [10]. Both GLUT2 and 4 can transport O-6-methylD-galactose, but GLUT3 shows little to no affinity. All three can transport the 6-fluoro
analog hinting towards extended hydrophobic interactions required in GLUT2 and
GLUT4 while GLUT3 has a low tolerance for any steric interactions. Although no
crystal structures of GLUT2-4 it is likely that they share similar structures however it is
difficult to know if they have more or less TM or ICH.

6

1.2.2

GLUT5

Class II transporter GLUT5 is the only known transporter that specifically transports
fructose and nothing else. In conjunction with GLUT2, they are responsible for most of
the fructose transport in the human body [27]. GLUT5 has been a topic of increasing
interest in recent years as it has been found to be overly active in breast cancer, while
at relatively inactive levels in normal breast cells [28]. Unlike most GLUTs, GLUT5 has
had a crystal structure released (Figure 2) and has shown large conservation between
GLUT1 but with some key differences. Like GLUT1 it is two bundles of six
transmembrane helixes however it has five intercellular helixes that are key for
stabilization. Inter-TM salt bridges are a common stabilizing force in major facilitator
superfamily transporters and are present only while GLUT5 is in the outward-facing
conformation. The observed salt bridges are formed between C-terminal helixes TM3,
4 and 5 and form between N-terminal helixes TM9, 10 and 11. Glu151 (TM4) forms
two salt bridges between two arginine residues: Arg97 (TM3) and Arg407 (TM11)
whereas Glu400 (TM10) also binds to Arg158 (TM5) and Arg340 (TM9) to complete a
stable network between the two terminals.
When GLUT5 transitions to the inward-open conformation, no C-N terminal salt
bridges are observed, and the conformational change in the transporter facilitates the
entering and exiting of the substrate. Further indicating a preference to outward-open
is the linking of Glu252 (ICH3) forming salt bridges with Arg407 (TM11), which is
broken upon the inward-open conformation. The most important transitions that take
place in GLUT5 occur in TM7 and TM10 as both undergo dramatic shifts to facilitate a
conformational change. TM7 shifts down towards the binding site as substrate enters
the central cavity whereas TM10 moves away from the binding site breaking the strong
7

interactions of Tyr382 (TM10) and Ile295 and Val292 (TM7) and allowing fructose
transport. These observations suggest TM7-TM10 interactions play an integral role in
transport kinetics [17].
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Figure 1.1: Comparison of interaction of C2-derivatives of furanose and pyranose ring forms of fructose
with GLUT5. Inhibitory constants were derived by monitoring inhibitory effect of analogs on the uptake
of [14C]-D-fructose into CHO cells expressing Glut5.

The binding site for fructose has been extensively studied by Holman et al. [13,
29-31], and determined that stereochemistry and presence of hydroxyls be vital to
substrate uptake (Figure 1.1). GLUT5 mediated fructose uptake was found to prefer
beta-anomers

over

alpha-anomers

determined

by

testing

C2-methylated

fructopyranose and fructofuranose analogs [13]. Alterations of stereochemistry of ring
hydroxyls or alkylation was found to dramatically limit affinity to GLUT5 with the notable
exception of the C2 position. When 2,5-anhydro-D-mannitol was tested it revealed that
the anomeric hydroxyl plays little to no role in GLUT5 fructose transport and that
GLUT5 effectively takes up fructose in its furanose form as opposed to its pyranose
form [29]. Cyclic oxygen has been found to be vital for uptake via GLUT5 as thio8

substitution led to six-fold loss of uptake was observed [32]. C2 and C5 stereocenters
were found to increase uptake during an anti-relationship when comparing 2,5anhydro-D-mannitol uptake vs. L-sorbose (Figure 1.2).

O
HO
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OH
OH

OH

54%
46%

Ki = 134 mM

D-psicopyranose
α = 22%, β = 24%
O
HO

OH
OH
OH

OH
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O

OH
OH

81%
Ki = 59 mM

HO
HO

OH

O

OH
OH
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OH

HO
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L-sorbose
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D-psicofuranose
α = 39%, β = 15%
4%

OH

O

HO

HO
HO

S

OH
OH

OH
5-thio-D-fructose
Ki = 96 mM

Figure 1.2: Conformer ratios and inhibitory constants for fructose uptake via GLUT5 for D-fructose, Dpsicose, and D-tagatose.

The Holman team envisioned a locked series of analogs may provide key
insight in GLUT5 binding and potentially series of GLUT5 specific probes (Figure 1.3).
These probes were split into type I and type II and differed in existence of the C1
hydroxyl with type I maintaining while type II removed. Type I scaffolds were tested to
inhibit D-fructose uptake in the presence of both C1 hydroxyl and ether and was found
to inhibit uptake in both cases [31]. In the presence of a carbonyl, oxazolidine uptake
was nearly 4-fold higher than its thio counterpart pointing towards key oxygen
interaction with the transporter. Type II analogs failed to inhibit D-fructose uptake
regardless of stereochemistry, indicating that C1 and C6 oxygens are vital for transport
in GLUT5, but C1 acts primarily as an H-bond acceptor or a similar coordination with
the transporter. These studies in conjunction with crystal structure have given a good
image on what GLUT5 will tolerate to induce binding, but severe limitations persist in
9

understanding size and functionalization of payloads that transporter permits to pass
through.

6

HO
HO

O

1
2

I
Derivatives of
D-fructose (R = H)
D-fructose (R = Bn)
L-sorbose (R = H)
L-sorbose (R = Bn)

OH(OR)
NH

O

6

HO

X

HO

Ki, mM
25 (X = S), 12 (X = O)
32
9
7
17
12
3

O

2

II
Derivatives of
L-arabinose
D-arabinose
D-xylose
D-ribose

NH
S

O

Ki, mM
123
104
106
109

Figure 1.3: Bicyclic furanose analogs testing GLUT5 uptake conditions

1.3 GLUTS in Therapy
As discussed previously, PET imaging is one of the most successful utilization
of overactive GLUT transport in diseased cells (mainly cancer), but it is not the only
one currently in use and development. Quantifying transporters in the membrane has
several limitations and involve time-consuming experiments such as western blots or
extensive mutagenesis. Monitoring carbohydrate mimics uptake gives a quick and
telling analysis of relative expression and activity of transporters that are being
specifically targeted.
1.3.1

Carbohydrates as diagnostic probes
The

apparent

relationship

between

deregulated

carbohydrate

uptake/metabolism and disease has triggered interest in GLUT-targeting diagnostic
probes. SAR and kinetic analysis of various substrates (described above) have led to
the development of radiolabeled probes as well as fluorescent analytical probes. The
understanding that C2 and C6 hydroxyls do not play a role in the uptake provided
handles for halogenated analogs to act as radiotracers to measure glucose uptake in
10

diseases. 2-Deoxy-D-glucose (FGD) was first reported by Pacak and co-workers in
1968 [33], and the first

F-labeled analog (18F-FGD, 1, Figure 6) was reported by

18

Brookhaven National Laboratory in 1978 [34].

F-FDG is rapidly transported into a

18

cancerous cell due to its increased metabolism and undergoes phosphorylation to
prevent excretion. Increased intracellular accumulation of

F-FDG in cancerous cells

18

provides key insight into important cancer characteristics namely enhanced glucose
transport as well as enhanced phosphorylation.

F-FDG has seen wide use as a

18

predictor of tumorigenesis [35-39]. However, it is ineffective with a large number of
cancers (including breast cancers) that have reduced glucose uptake capacity [2, 40],
and produces false-positive hits due to accumulation at the of inflammation [41, 42].
Due to limitations of FDG needing to be phosphorylated to remain in the cell to
accurately measure glucose transport independent of cellular phosphorylation. [123I]6-deoxy-6-iodo-D-glucose (6DIG, 2, Figure 1.4) was first synthesized by Wassenaar
to act as a tracer unaffected by phosphorylation [43]. Biological studies of 6DIG
performed by Henry and co-workers [44] confirmed that 6DIG underwent cellular
transport via GLUTs without phosphorylation making it a valuable tool in tracing
glucose transport. In vitro studies involving adipocytes of diabetic rats and obese mice
indicated 6DIG as a potential tool for determining glucose transport derivations in
diseases [45]. 6DIG was found to undergo preferential uptake in adiposities, and
cardiac cells, both with have high concentrations of insulin-regulated GLUT4 and was
proposed as a potential in vivo tool to measure insulin resistance. Using diabetic mice
and insulin-resistant fructose-fed rats, Perret, and coworkers [46-48] determined
glucose transport defects in vivo using 6DIG.
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Class II fructose specific transporter GLUT5 has gained considerable attention
as a potential cancer target due to its alleged role in cancer development [7]. Designed
by Maeda and co-workers [49], 1-[18F]-Fluoro-1-deoxy-D-fructose (3, Figure 1.4) acted
as a tracer in to specifically target GLUT5. Synthesized in two steps from 2,3,4,5-diO-iso-propilidene-1-O-(trifluoromethane sulfonyl)-D-fructose, 1-[18F]-Fluoro-1-deoxyD-fructose rapidly passed through kidney and liver when tested in rat and mouse tumor
grafts. Development of 6-fluoro-6-deoxy-D-fructose (4, Figure 1.4) [38, 50], found a
tracer capable of entering murine EMT-6 and the human breast cancer MCF cells. 6[18F]-FDF acted as hexokinase substrates and was rapidly metabolised in vivo.
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Figure 1.4: Glucose and fructose-based PET imaging probes

The next generation of radiotracer probes was derived from 2,5-anhydro-Dmannitol based on its high affinity towards GLUT5. Niu tested PET imaging agent [39]
1-[18F-fluoro]-1-deoxy-2,5-anhydro-D-mannitol [51] (5, Figure 1.4) in breast cancer
solid tumours. Results displayed rapid excretion after internalization by cancerous
cells requiring optimization to increase retention. 3-(18F)fluoro-3-deoxy-D-fructose (6,
Figure 1.4) developed by Cheeseman et al. [52] showed fructose specific transport by
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a series of competitive uptake inhibition studies and was shown to enter multiple
cancer cells lines including EMT-6, CHO, and MCF. Although not as successful as
glucose PET imaging tracer, preliminary results have warranted development of more
stable and easily retained fructose analogs for PET imaging in the future.
1.3.2

Carbohydrates in chemotherapy
Glycoconjugation provides a potentially elegant way of preferentially targeting

cancerous cells in the presence of normal, healthy cells by targeting the overactive
metabolism of cancer [14]. Glufosfamide (8, Figure 1.5) acted as a prodrug, remaining
inactive until cleavage of the glucose after endocytosis into the cell and was one of the
first glycoconjugated drugs used [14]. Glufosfamide failed to pass phase II clinical trials
for unknown reasons, however, did specifically target glucose transport and provided
a potential starting point. Glycoconjugation has been used in an attempt to increase
specificity for existing drugs such as chlorambucil which was conjugated to several
sugars in an attempt to improve specificity and cytotoxicity [53]. Chlorambucil was
conjugated with 63 compounds including glucose (7, Figure 1.5), mannose, galactose,
and xylose, and conjugation were shown to improve cytotoxicity up to 8-fold [54]. It is
unknown if chlorambucil’s increased cytotoxicity was caused due to a GLUT-transport
or increased accumulation in the cell due to sugar conjugation but it is a likely
hypothesis. Conjugates were not limited to chlorambucil and have been developed for
the following (not limited to) anticancer agents: azinomycin, clioquinol, adriamycin,
warfarin, cyclopamine, 8-[O6-(4-bromothenyl)-guanine, quinolinyl and methane
sulfonate, and paclitaxel (Taxol), with varying success [14].
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Lactate dehydrogenase (LDH) inhibitors [55] were developed with the intention
of selectively target tumors and act as a photosensitizer [56]. LDH inhibitor N-hydroxy
indole (NHI) (9, Figure 1.5) [55] conjugated of glucose or mannose lead to a noticeable
increase (4.5-fold) in antiproliferative effect as well as a similar increase in inhibiting
LDH. Likewise, glucose conjugates of 5,10,15,20-tetrakis-2,3,5,6-tetrafluorophenyl2,3-(methanol(N-methyl) iminomethano) chlorin (10, Figure 1.5) were developed with
the intention of being a selective and more potent cytotoxic drug (H2TFC-S-Glc).
H2TFC-S-Glc did show more potency than other photosensitizers but remained nonspecific, this is likely due to the substitution of the anomeric hydroxyl (shown previously
to be vital for binding) and points to non-GLUT mediated uptake behind the loss of
specificity.
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Figure 1.5. Carbohydrates as cancer-directing encore in drug delivery
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Platinum (Pt) and palladium (Pd) complexes have seen incredible success in
cytotoxicity, but due to lack of specificity lead to horrific side effects, glycoconjugation
was attempted to increase specificity in a number of complexes. Tanaka et al. [57]
have tested C2-Pt and C2-Pd glucose conjugates in vivo on gastric cancer cells that
have been shown to be cisplatin-sensitive and cisplatin-resistant. Like typical cisplatin,
apoptosis was induced by coordination between grooves of the DNA and preventing
DNA replication. However, both compounds were found to be less effective and no
more specific than typical cisplatin. It is unknown whether the compounds were
transported via GLUTs or through some other process and the glucose may have
caused steric issues with coordination in DNA to decrease activity.
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Figure 1.6. Glucose as a delivery platform for platinum compounds.

Lippard, and coworkers [58] were able to identify GLUT preference of C1 and
C2 conjugation of Pt and Pd derivatives after screening several isomers. These results
agree with previous observations studies [9, 24]. In a separate studies, Lippard and
coworkers have designed and evaluated C6-Pt conjugates (11-14, Figure 1.6) that
differed in the linker length between Pt and the carbohydrate.[59] Using bacterial
xylose transporter XylE, which is very similar to GLUT1, molecular docking studies
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showed conjugates undergoing H-bonding interactions with key residues Gln288,
Gln168, Gln175 and Tyr298 pointing towards GLUT-mediated uptake.
4,6-O-ethylidene-α-D-glucose (EDT) in the presence of conjugates 11-14 was
found to inhibit uptake indicating GLUT1 as the route for intercellular uptake and was
found to decrease as linker length was increased [60]. Aglycone 13 was found not
undergo GLUT-mediated uptake and likely go through passive diffusion [59]. Ptglucose conjugates were found to have similar cytotoxicity of aglycone 13 and higher
than cisplatin in a number of human cancer cells. Cytotoxicity was experienced after
shorter incubation periods indicating the difference in kinetics between facilitative
GLUT transport vs. that of passive diffusion that aglycone and cisplatin rely on. The
compounds 11 and 12 were found to platinate DNA leading to cell apoptosis, with the
number of platinated residues relatively similar to oxaliplatin. The uptake of 11-14 was
also found to different extend to depend on the organic transporter 2 (OCT2, involved
in the uptake of 14), with 11 showing more GLUT-specific uptake that other analogs.
Further evaluation showed 11 to be more cytotoxic in cancer vs. normal cells, giving a
good platform for further development of cancer-specific therapeutic agents.
Glycoconjugation has also been used in an attempt to increase selectivity for
a variety of other nonspecific methods of drug delivery. Nanoparticles have been
widely studied as potent delivery systems for highly cytotoxic payloads but suffer from
lack of specificity [61]. In an attempt to increase specificity glycoconjugation with
nanoparticles has been attempted with varying success [62]. Li and co-workers [62]
developed glucose-conjugated chitosan nanoparticles in an attempt to encapsulate
doxorubicin with limited success. Doxorubicin-loaded nanoparticles entered 4T1
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cancer cells up via GLUTs and were four times more cytotoxic than non-glucoseconjugated nanoparticles [63].
Glycoconjugation has not been limited to just cancer and has found success in
delivering payloads through the blood brain barrier due to high amounts of GLUT1 [64,
65] as well as other barrier structures in the brain [66]. A successful example was
ibuprofen-glucose conjugation resulting a dramatic increase in drug delivery to the
brain with a three-fold increase in concentration [15]. The massive challenges BBB
penetration and water solubility represent for most small molecule drugs prodrug
development with glucose provides an elegant solution to both of these issues and
represents potentially effective drug delivery system for future drugs [67].
1.3.3

Fluorescent GLUT Probes
Targeting GLUTs has been attempted a variety of fluorescent conjugates.

However, the only fluorophore found to pass through GLUTs was green-fluorescent 7nitrobenzofurazan (NBD). Conjugation of amino sugars – 2-Amino-2-deoxy-D-glucose
(G) [68], 1-deoxy-1-amino-D-fructose (F) [69], and 1-amino-2,5-anhydro-D-mannitol
(M) [70] with NBD has produced a probes specific for certain GLUTs (Figure 1.7).
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Figure 1.7: Green fluorescent GLUT-targeting probes

NBDG is glucose dependent [68, 71], and is likely passes through most class
I transporters. NBDF uptake is facilitated by glucose- and fructose-transport and is
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likely to rely on GLUT2 and GLUT5 [69]. MNBD uptake depends only on fructose and
likely passes specifically through GLUT5, suggesting some preference of the
transporter towards the locked furanose ring. Altogether, NBDG, NBDF, and NBDM
allow assessing the efficiency of glucose-specific transport, non-specific transport and
fructose-specific transport, respectively, providing convenient tools for quick analysis
of carbohydrate transport efficiency in various cells. All three probes were found to be
phosphorylated inside the cell, ensuring their cellular accumulation and retention [72].
Limited attempts to produce red fluorescent probes by conjugating carbohydrate to
cianine5 (Cy5) dye resulted in a loss of GLUT-mediate uptake [69], leaving room for
further evaluation of transporter preferences in substrate selection. Fluorescent
probes have wide room for improvement as NBD competes with auto-fluorescence of
cells in the green region and various colors provide an opportunity of tracking various
transporters activity simultaneously.
This thesis work focuses on our attempts to develop fructose uptake
dependent fluorescent probes. Synthesis and probe design will be discussed in
Chapter 2 while cellular studies will be discussed in Chapter 3. Future research plans
for additional probes and cancer types will be summarized in Chapter 4.
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Chapter 2
Blue Fluorescent Probes GLUT-Mediated Uptake in Breast Cancer
2.1 Introduction
Carbohydrate uptake in mammalian cells is facilitated by membrane proteins
called GLUTs which perform gradient-dependent carbohydrate transport [1, 2].
Expression of GLUTs varies throughout the body and can be viewed as a physiological
characteristic of the tissue. Mutations of GLUTs have been linked with several medical
conditions [3] while alterations to GLUT activity and regulation are characteristic for
the metabolically-compromised cell, including cancer cells [4]. GLUT research has
been mainly focused on widespread glucose transporter GLUT1 due to its high activity
in various cancers. Recent findings have increased interest in the fructose-specific
GLUT5 that appears to be expressed in various cancers, while absent in the
corresponding non-cancer tissues [5].
The kinetic analysis of carbohydrate transport via GLUTs led to the
development of the transport model that included the binding of the substrate to the
extracellular site of the transporter, followed by the conformational change in the
enzyme and the translocation of the substrate to the intracellular or endofacial side of
the membrane [6]. Initial binding of the substrate to the transporters was found to vary
with the structure of a carbohydrate, i.e. to depend on sugar conformation and the
presence and stereochemistry of hydroxyls [7-11]. The understanding molecular basis
for sugar-transporter interaction facilitated the development of biochemical probes to
analyze transport efficiency, and dissect the membrane portion from the total GLUT
expression. The latter provides the possibility for cell differentiation based on profiling
The following material is in preparation for submission to a journal for publication.
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the membrane GLUTs. GLUT-targeting imaging agents and drugs conjugates are of
interest to distinguish and kill metabolically-compromised cells [12], or to penetrate the
blood-brain barrier [13]. Therapeutic approaches also include inducing a nutrient
deficit in cancers, thus stimulating the development of carbohydrate uptake
modulators.
Current knowledge of GLUT-substrate interactions and the transport capacity
of GLUTs is currently limited and requires significant study to determine. Conjugation
of amino sugars – 2-Amino-2-deoxy-D-glucose [14], 1-deoxy-1-amino-D-fructose [15],
and

1-amino-2,5-anhydro-D-mannitol

[16]

to

the

fluorescent

7-nitro-2,1,3-

benzoxadiazole (NBD) has led to effective GLUT uptake probes. However, the efforts
to produce fluorescent conjugates of other colors (Cy5-fluorophore) failed, and GLUTCy5 conjugate showed to lose GLUT-mediated uptake [15]. Coumarins are aromatic,
blue fluorescent molecules with a similar size to NBD with an easily substituted C4
position to make a multitude of probes. GLUT2 and GLUT5 have been shown to be
the two primary transporters responsible for fructose transport but whether they both
transport fructose in its pyranose or furanose form remains unclear [17]. In this chapter
the synthesis of ManCou1, 2 and 3 as well as their effectiveness as imaging probes in
various cancerous and normal cell lines.
2.2 Materials and Methods
Materials and methods: Ethanol (ACS/USP Grade, 190 Proof) was purchased from
Pharmaco-Aaper, USA. Sterile DMSO (25-950-CQC, 250mL) was from Cellgro, USA.
RPMI-1640, DMEM/, Penicillin/Streptomycin, FBS (Fetal Bovine Serum), Sodium
Pyruvate (100 mM), 0/25% Trypsin-EDTA (1X), Hank’s buffer, PBS (phosphate
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buffered saline solution), and RPMI-1640 were was from Life Technologies, USA.
Cholera Toxin, Vibrio cholerae, Type Inaba 569B, Azide Free was from Calbiochem,
EMD Millipore, USA. Life Technologies, USA. PBS 1X solution was from Janssen
Pharmaceutica, Belgium. LIVE/DEAD® Viability/Cytotoxicity Kit, for mammalian cells
was from Invitrogen, USA.
Chemical reagents used for the synthesis were purchased from Aldrich.
Column chromatography was performed using SiliCycle silica gel (230-400 mesh).
Purification of NBD conjugates for cell studies was performed on Agilent HPLC 1200
Series equipped with fraction collector from Agilent Technologies, using Phenomenex
C18 column (Luna 5u C18(2) 100A, 250x4.60 mm, 5 micron) using MeOH:H2O as a
mobile phase. Structural analysis of compounds was carried out with 400 MHz Varian
NMR instrument. Spectra are reported in parts per million (ppm) relative to the solvent
resonances (δ), with coupling constants (J) in Hertz (Hz). UV-vis spectra were
recorded on a Cary 100 Bio spectrophotometer from Agilent Technologies. Highresolution molecular mass was obtained with Orbitrap Elite mass spectrometer. UV
spectra were obtained with Cary-Bio-100 UV-vis spectrometer. Fluorescence spectra
were obtained with a FluoroMax-4 spectrophotometer. 96-well plate analysis of cell
fluorescence was carried out with Victor3 fluorescence plate reader (excitation at 385
nm). Confocal images were taken with Olympus FluoViewTM FV1000 using the
FluoView software.
Chemical

synthesis

of

ManCou

probes:

(2S,3S,4S,5R)-3,4-dihydroxy-5-

(hydroxymethyl)tetrahydrofuran-2-carbaldehyde (1) (1 mmol) and the corresponding
C4-substituted 7-aminocoumarin (1 mmol) were dissolved in 10 ml of methanol. 0.5 M
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HCl was used to adjust the pH to 5.8 followed by addition of NaCH3CN (1.2 mmol) to
the reaction mixture. The solution was stirred at room temperature while the pH was
maintained at 5.8 by periodic addition of 0.5 M HCl until the starting material was no
longer detectable by TLC. The mixture was then concentrated to a small volume under
reduced pressure, and the concentrated residue was separated by the semipreparative HPLC (Kinet 2.6 u HILIC 100A) using a various proportion of water-MeCN
as an eluent. The composition of the final product was confirmed ESI, HRMS, 1H NMR
and 13C NMR.[18]
Cell Culture: MCF-7 and MCF-10A cells were seeded from frozen standards
purchased from ATCC in 10 cm dishes under standard conditions (37 Co, 5% CO2 /
90% air). MCF-7 cells grown in RPMI-1640 growth medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin both
purchased from Thermo-Fisher. MCF10A was grown in DMEM growth media
supplemented

with

10%

heat-inactivated

fetal

bovine

serum

(FBS),

1%

penicillin/streptomycin, and cholera toxin (100 ng/ml). MCF7 was passaged with
trypsin every five days, MCF-10A every ten days with media being changed 24 hours
after seeding.
Preparing ManCou solutions: ManCou1 and 2 were dissolved in a solution of 10%
DMSO/90% Millipore water for stock solution. ManCou3 was dissolved in 70%
DMSO/30% Millipore water for stock solution. All solutions for testing were diluted from
stock using Hank’s buffer solution purchased from Thermo Fisher.
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96-well plate fluorescence studies: At >85% confluence cells were collected and
plated in 96-well flat bottom plates (20,000 cells/well) purchased from and allowed to
grow for 24 hours. Cells were then washed with warmed (37 Co) Hank’s balanced
buffer solution and treated with ManCou fluorescent probes (concentration varies) in
Hank’s and incubated at 37 Co and 5% CO2 for 10 min. After incubation, the probecontaining solution was removed, and cells were washed with warmed Hank’s (3 x 100
µL) buffer. Fluorescent data was immediately collected using Victor3 plate reader and
using WallacTM umbelliferone (excitation 355 nm, emission 460 nm, 1.0 s) protocol. All
tests were done in duplicate on each plate.
Inhibition studies: Using 96-well plate method fluorescence of ManCou probes in
cells war measure in the presence of varying concentrations of glucose, fructose,
glucosamine, MNBD, GNBD, and cytochalasin B. Separately, complete culture media
was used to establish the impact of nutrients on ManCou uptake. Cell incubation,
washing, and data collection was conducted as stated above.
Confocal fluorescence studies: At >85% confluence cells were collected and plated
(20,000) in 35 mm glass-bottom confocal dishes (MatTek) and allowed to grow in their
respective growth media for 24 hours. Cells were then washed with warmed (37 C°)
Hank’s (2 x 1 mL) before being incubated with ManCou solution in Hanks (1 mL, 37
C°, 5% CO2) for 10 min. After incubation cells were again washed with warmed Hank’s
(3 x 1 mL) and leaving 1 mL of Hank’s for images. Images were taken using Olympus
FluoViewTM FV1000 using the FluoView software. 60X oil suspended lens cells were
used to observe fluorescent activity with the following conditions; filter: DAPI, laser:

32

405 (45% intensity), excitation: 10 µs/pixel. Z-stacking was done using FluoView
software and depth command.
Fructose preconditioning: MCF7 cells, grown in the standard growth medium, were
passaged and maintained for ten days in i) the standard medium supplemented with
fructose (11 mm) to produce fructose-fed MCF7’ cell culture, and ii) in RPMI-1640
medium supplemented with dialyzed FBS (10%) to produce fructose-deprived MCF”
cells culture. The MCF” cells were then maintained for ten days in the standard
medium to produce fructose-refed MCF7* culture. The medium was changed 24 h
after passaging of cells and every two days.
2.3

Synthesis

and

Computational

Analysis

of

Mannitolamin-Coumarin

Conjugates (ManCou Probes)
Several coumarins differing in the functional groups at the C4 position (Figure
2.1) were chosen to assess the possibility to transport extended aromatic system
through GLUTs and test the impact of steric, H-bonding and electronic interactions.
ManCou1 (H) represents a plain aromatic system with weakly H-bonding carbonyl
group that is not expected to exhibit any interactions with the transporter. ManCou2
(CH3) acts as a weak electron donating group that appears to increase electron density
of coumarin aromatic system and possibly contributes to the enhanced H-bonding
capability of the carbonyl group. ManCou3 (CF3) acts as a strong electron withdrawing
group deactivating the aromatic system of coumarin and thus increasing its potential
capability of π-acceptor. Additionally, the presence of halogens is known to induce
halogen-π interactions within proteins, and CF3 group, in particular, is capable of
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stabilizing interactions with aromatic systems [19, 20]. Thus, H-bonding and aromatic
interactions would be expected for ManCou3 within the transporter.

HO
HO

ManCou1

OH
O

ManCou2

ManCou3

H
N

ManCou1: R = H
ManCou2: R = CH3
ManCou3: R = CF3

R
O
O

Figure 2.1. ManCou1-3 probes and their electrostatic properties

The synthesis of conjugates was based on the reductive amination of
(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-carbaldehyde (1)
with the corresponding 7-aminocoumarin, resulting in ManCou 1-3 conjugates
(Scheme 1). To access aldehyde 1, D-(+)-glucosamine was carried through a
Tiffeneau-Demjanov rearrangement with an acidic resin in the presence of NaNO2 [21].
The aldehyde 1 was isolated in acceptable yield (84%) and was used in the
subsequent reactions without purification. The ManCou conjugates were purified by
high-pressure liquid chromatography (HPLC) using a gradient of ACN:water and
analytical (4.5 Å) C18 reverse phase column (Phenomenex). Structures of ManCou13 probes were confirmed with NMR spectroscopy and Mass Spectrometry.
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Scheme 2.1. Synthesis of ManCou probes

Optical properties of ManCou1-3 were analyzed through UV-vis (Cary-Bio-100)
and fluorescence (FluoroMax-4). The UV and fluorescence (Figure 2.2) spectra for
ManCous 1-3 reflected the impact of a methyl- and trifluoromethyl- substituents on the
π-system of the fluorophore, with blue- and red-shift observed for ManCou2 and
ManCou3, respectively. The relative quantum efficiencies of ManCous 1:2:3 were
established as 0.9:1.0:0.30 (determined for 385 nm excitation wavelength). The
absolute quantum yields were determined based on the optically matching solution of
anthracene [22] (20 μM in ethanol, ϕ = 0.27) as 0.26, 0.30, and 0.10 for ManCou1,
ManCou2 and Mancou3 (20 μM in DMSO/H2O 9:1, v/v), respectively.
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Figure 2.2. UV-vis and fluorescence spectra of ManCou1-3

To gain insight into the ManCou interaction with GLUT5, molecular docking of
DFT-optimized structures of coumarin conjugates into the exofacial cavity of a
mammalian fructose transporter GLUT5 (PDB code: 4YB9) using Autodock4 [23] was
carried out. For each ManCou probe, the resulting complexes were ranked, and the
complexes were analyzed to identify the position/binding of conformers.
A

B

ManCou1

ManCou2

C

ManCou3

Figure 2.3. Docking analysis of ManCou1-3. Docking analysis performed with Autodock4. Models
visualized with PyMol.

Overall, the analysis of complexes showed the ManCous to bind with the
uptake relevant residues through the 1-AM moiety but accommodate different
orientations of the fluorophore (Figure 2.3). All three probes were found to H-bond with
Tyr32, Gln167, Gln289, and the Glut5-specific Asn294 – residues also found to be
involved in fructose uptake through GLUT5 [23]. While the binding of 1-AM between
three complexes involved the same residues, the H-bonding sites at 1-AM were altered
to accommodate the change in the position of the fluorophore. For ManCou1, the large
population of conformers was found to orient the coumarin moiety towards His419 and
Trp420 – residues found to be critical for fructose uptake (Figure 2.3A) [23]. For

36

ManCou3, nine out of ten conformational isomers had the coumarin moiety oriented
away from these residues into the more open space (Figure 2.3C). Interestingly, for
ManCou2 (Figure 2.3B), conformations similar to those of ManCou1 and ManCou3
were detected, suggesting the probe to have duality, as sensed by malignant cells.
However, a higher level modeling would be required to assess a true binding site(s)
for these probes and further identifying key interactions contributing to the differences
in their uptake behavior and cellular impact.

2.4 Analysis of ManCou1-3 uptake
The uptake analysis of ManCou1-3 was carried out in breast cancer
(adenocarcinoma) MCF7 cells. MCF7 cells have been previously studies for GLUT5mediated uptake [15, 24-26] thus providing a good platform for initial probe evaluation.
MCF7 cells were cultured according to standard protocol, seeded in the 96-well plate
(20000 cells/well) and maintained to adhere for 12 h. Cells were then treated with
varied concentrations of ManCous 1-3 (in Hank’s solution and media) for 10 min at 37
°C, and fluorescence was measured after removal of the probe and cell wash. As a
result, efficient concentration-dependent uptake was observed for all probes with
ManCou1 having the highest uptake and ManCou3 having the lowest uptake (Figure
2.4A). The transported probe remains in the cells even after post-incubation in a probefree media and repeated washing. This is in agreement with previous observations,
where 2,5-anhydro-D-mannitol was found to be a suitable substrate for
phosphofructokinase-1 [27-29]. Accordingly, the lack of back transport is a significant
point because GLUT transporters, being antiporters,
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take up and excrete

carbohydrates, but not the phosphorylated products [30]. The comparative analysis of
non-conjugates coumarins with ManCou (Figure 2.4B) shows that the presence of 1AM drastically enhances the uptake, putatively contributing to facilitative internalization
of probes rather than passive diffusion (as for non-conjugated coumarins).
A

B

Figure 2.4. Uptake analysis of ManCou probes in MCF7 cells. A) ManCou probes exhibit concentrationdependent uptake. B) 1-AM facilitates coumarin uptake (measured for 20 μM ManCou1-3 vs. nonconjugates coumarins). Data represents the Gained Fluorescence (excitation at 385 nm) measured in a
96-well plate settings after 10 min incubation of cells with probes in Hank’s buffer. Fluorescence values
corrected for the quantum yield of ManCou probes.

24 hours after the uptake no ManCou-induced fluorescence activity was
observed, suggesting cellular metabolism of the fluorophore. This observation, as well
as no saturated fluorescence point being found, points toward ManCou sugar base
undergoing phosphorylation as it enters the cell to and eventually being excreted as a
metabolite. If the sugar base was not phosphorylated, the probe could easily be
excreted once the media containing the fluorophore was removed, which was not
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observed even after 30min post incubation. Further testing is needed to determine
whether the fluorophore itself is metabolized or passively diffuses out of the cell.
The uptake efficiency of ManCou probes appears to change with the change
in electronic properties of coumarins. Thus, from three probes, ManCou1 is taken up
most avidly, ManCou2 is taken up with ~25%, and ManCou3 with 4-fold lesser
efficiency (Figure 2.4A). The analysis of the uptake kinetics through Michaelis-Menten
method [18] showed all three probes to have concentration-dependent saturable
uptake (Figure 2.5), exceeding that of fructose by nearly 1000-fold (15-17 µM for
ManCou1 and 2, and 35-37 µM for ManCou3).
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Figure 2.5. Kinetic analysis of ManCou1-3 uptake using Michaelis-Menten Kinetics. Plots depict
1/fluorescence vs. 1/concentration using data obtained upon treating cells with 1-100 µM ManCou
concentrations Plots obtained with SigmaPlot13.

The Z-stack images obtained for MCF7 cells treated with ManCous 1-3 show
that while ManCou1 and 2 are localized within the membrane and in the cytosol,
ManCou3 is only present within the cell membrane. The drastic difference in probe
properties could be rising due to the extended binding of ManCou3 with GLUT5, and
particularly with Trp419. From all residues identified to bind ManCou3, the Trp419 is a
key residue located on the transmembrane helix 11 (TM11) of GLUT5 which may inhibit
the conformation shift between TM10 and TM7 required for the change from the
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occluded state into the inward open state. In such case, the protein is expected to be
locked in the outward-open conformation and prevent internalization of the substrate.
However, it would require a crystal structure with probe bound to confirm this notion.
ManCou 1

ManCou 2

ManCou 3

Figure 2.6. Confocal Z-stack images of MCF7 cells treated with 20 uM ManCou1-3 (10 min at 37 °C, 405
nm excitation, 461 nm (DAPI) emission, 60X objective).

To assess whether ManCou1-3 exhibit GLUT5 specificity, the impact of
nutrient carbohydrates, MNBD, GNBD, and cytochalasin B on the probe uptake was
evaluated. Glucose, fructose, and glucosamine were used as competitive inhibitors of
ManCou uptake. The impact of glucose and fructose on the uptake was used to
establish the involvement of glucose transport and fructose transport, respectively, in
the ManCou uptake. Upon addition of glucose up to concentrations exceeding
physiological (1-50 mM) no inhibition of ManCou uptake was detected (Figure 2.7A).
Likewise, no significant change in the uptake efficiency of ManCou probes was
observed upon crying out uptake analysis in culture media, as opposed to Hank’s
buffer (Figure 2.7B). These results could rise from the significantly higher affinity of
ManCou probes to their biological target(s), resulting in a lack of interference of
nutrients in their uptake. ManCou uptake is however inhibited by MNBD, previously
shown to target GLUT5, while not impacted by GNBD (targeting glucose transport).
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The observation is suggestive of ManCou probes exhibiting the same mechanism of
uptake as MNBD, i.e. via GLUT5.
A

C

B

D

Figure 2.7. Inhibition of ManCou (20 µM) uptake with carbohydrates (A), culture media (B), MNDB (C),
GNDB (D), and cytochalasin B (E) in MCF7 cells. Data normalized by quantum yield.

To further assess the role other fructose transporters in ManCou uptake particularly the role of GLUT2 contributing ~12% to total fructose uptake in MCF7 cells
- cytochalasin B was used a non-competitive inhibitor of glucose uptake through
GLUTs 1-4. Addition of cytochalasin B in concentrations far exceeding the established
for GLUTs 1-4 (Ki = 2-10 µM) did not have impact on the uptake of ManCou probes,
showing the uptake to be independent of GLUT1-4. The use of glucosamine (up to 50
mM) as GLUT2-specific substrate also did not induce any effect on ManCou uptake,
further supporting the lack of GLUT2 participation in the uptake of ManCou probes.
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Overall, uptake inhibition studies strongly suggest that ManCou probes are
transported through fructose-specific transporter GLUT5.

Figure 2.8: Uptake of ManCous in MCF7 cells pre-conditioned with or without fructose. Comparative
analysis of ManCou uptake in fructose-fed (MCF7’), fructose-deprived (MCF7”) and fructose re-fed
(MCF7*) cells (normalized by MCF7). MCF7, cells grown in standard media; MCF7’, cells fed with
fructose; MCF7”, cells deprived of fructose; MCF7*, MCF7” cells re-fed with fructose. Data represents the
Gained Fluorescence. Fluorescence values corrected for the quantum yield of ManCou probes.

Prolonged exposure of cells to fructose has been shown to primarily increase
expression of GLUT5 [31]. Hence, preconditioning of MCF7 cells with fructose has
been carried out to gather further evidence of GLUT5-mediated uptake of ManCou13. To produce fructose-fed cells, MCF7 cells were maintained in the standard growth
media supplemented with 11mM fructose for ten days. The uptake analysis of
ManCu1-3 probes in fructose-fed MCF7’ cells showed up to 3-fold increase in uptake
of ManCou probes (Figure 6A). These results are consistent with previously reported
MNBD uptake with fructose preconditioned MCF7 cells [16]point towards GLUT5
driven uptake of ManCou as a result of increased activity of fructose transport or
metabolism. Starving MCF7 cells of fructose by maintaining them in the dialyzed media
for ten days decreased ManCou uptake by 2-fold while re-feeding the starved cells by
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maintaining them in regular media (non-dialyzed) regenerated the levels of the uptake.
Whether the observed changes result from the alterations in GLUT5 expression or are
driven by the changes in metabolic activity of preconditioned cells has not yet been
determined.
Overall, the inhibition and cell preconditioning studies indicate that Manzcou13 probes are preferentially transported through GLUT5. Within this set of probes,
ManCou1 behaves as a transport probe, showing clean gradient-driven uptake
kinetics of first-order in the ManCou. ManCou3 appears to be an effective transportlabeling probe showing clean receptor-ligand kinetics. ManCou2, overall, shows
behavior is similar to ManCou1 (i.e. is transported through the membrane). However,
some interactions with the protein appear to deviate the uptake from pure gradient
driven first order kinetics.

2.5 ManCous as GLUT5 expression and fructose metabolism probes
To further determine ManCou’s method of transport, several different human
cancerous and noncancerous cell lines known to have different expression of GLUT5
were treated with ManCou 1-3 probes. In normal breast MCF10A cells, known to have
minimal levels of GLUT5 expression, ManCous have shown significantly lesser uptake
compared to the cancerous counterparts. This is expected due to documented
increase in carbohydrate uptake in cancerous cells when compared to their
noncancerous equivalents. Interestingly H9C2 a cardiac cell line showed minimal to
no uptake of ManCou1 or 2. However, labeling of the membrane with ManCou3
showed results similar to that of MCF7 cells. While the expression levels of GLUT5 in
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H9C2 are not established, it appears that the differences in fluorescence induction by
ManCou1 vs. Mancou3 may be indicative of a sufficient membrane expression of
GLUT5 but the lack of metabolizing enzymes to drive gradient-dependent transport of
ManCou1. This observation provides grounds for further analysis of protein (GLUT5
vs. metabolizing kinases) expression in cardiac cells. Subsequently, ManCou probes
could be effectively used to identify GLUT5 expression and fructose metabolism in
cells.

A

MCF10A

MCF10DCIS.com

MCF7

MCF10neoT

MCF10Ca1a

B

C

Figure 2.9. ManCous1 and ManCou3 in the MCF10A model (confocal images): A) cells with no probe;
B) cells with the probe; C) cells with the probe (fluorescence). MCF10A, non-cancer; MCF10DCIS.com,
undifferentiated lesions, MCF7, adenocarcinoma; MCF10-neoT, premalignant; and MCF10Ca1a, highly
malignant. Images taken at 405 nm laser at 461 nm (DAPI) emission (20X objective).

Considering that there is currently a significant lack in understanding what
impact fructose uptake inhibition may have on cells, we have evaluated ManCou3 in
a MCF10 model that systemically demonstrate breast cancer initiation, development,
and progression [32]. As a result, blocking Glut5 with ManCou3 exerted cytotoxic
response in malignant cells but not in normal or undifferentiated cells (Figure 2.9).
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2.6 Conclusions
Here three novel carbohydrate-mediated probes have been developed and
tested, each with their unique kinetics of intercellular uptake. ManCou1 and 2 both
appear to pass through GLUT5, ManCou3 appears to remain inside the cellular
membrane. Considering the link between GLUT5 activity and carcinogenesis [33]
targeting GLUT5 appears to give a new way to achieve cancer-specificity of
therapeutics or imaging agents. In fact, ManCou probes appears to exhibit desired
cancer specificity. Moreover, blocking Glut5 with ManCou3 exerted cytotoxic response
in malignant cells but not in normal or undifferentiated cells. These results may
potentially lead to a procedure for relatively quick analysis on cancer aggressiveness
based on fluorescent intensity and accumulation. Also, ManCous provide a proof of
concept that using carbohydrate mimics, such as 1-AM, may be beneficial for targeted
drug delivery.
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Chapter 3
Synthesis of Locked Fructose Analogs
3.1 Introduction
MNBD (1-amino-2,5-deoxy-D-mannitol conjugated to NBD) has been shown to
preferentially transported through GLUT5 with significantly higher affinity for fructose.
However, it is unclear what exactly leads to the observed increased affinity. One of the
possibilities is that GLUT5 may have a preference for the five-member ring
conformation in addition to hydrophobic interactions induced by the fluorophore.
Fructose equilibrates between two different ring conformations; furanose (fivemembered ring) and pyranose (six-membered ring) with 25% and 75% populations
respectfully. GLUT5 affinity towards these ring conformations are unclear due to all
probes used to determine it exist as anomeric mixtures [1, 2]. To alleviate these
ambiguous results, probes need to be developed with locked ring conformations to
understand if GLUT5 is specific for pyranose or furanose forms of the sugar.
Fructose has four stereocenters. However, the importance of their absolute
stereochemistry is unclear. Altering these stereocenters may lead to increased
binding affinity towards the transporter which may lead to potentially potent inhibitors.
Using organic synthetic techniques to install each stereocenter will allow the
construction of several unique probes to determine importance of stereochemistry on
GLUT5 uptake. This chapter outlines the goals and current progress of probe
synthesis.
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3.2 Results and Discussion
While synthetic development proceeded smoothly for initial reactions in
relatively high yields, the first significant challenge in the synthesis was the
apparently simple oxidation of the epoxy system. Common oxidation techniques
such as PCC and Swern yielded little to no results, however when 1 was subjugated
to Parikh-Doering conditions the resulting aldehyde was obtained in relatively high
yield. Wittig olefination proceeded smoothly followed by syn-selective opening using
Pd tetrakis in the presence of benzyl alcohol. Followed by DIBAL reduction which
lead to relatively high yield of 83%. After the isolation of 3 the initial goal was to
oxidize the epoxy alcohol, extend and repeat the Pd-catalyzed opening. However,
TEMPO oxidation techniques to selectively oxidize the primary alcohol did not
proceed. Parekh-Doering was then conducted to attempt to get the aldehyde but
ultimately proved unsuccessful.

BnO

OH

1

OH
BnO
3

1. Parikh-Doering Oxidation
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2. Wittig olefination
3. Pd-catalyzed
syn-selective opening
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Scheme 3.1: Overall synthesis of alpha-NBD pyranose probe
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1. O3/PPh3
2. NaBH4
3. TsCl

OH OH
OBn OBn

1. H2/Pd
2. (PhO)2P(=O)N3
3. NBDCl, NaHCO3
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2. SAE

OBn
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OBn
- +

CO2Me

2

3. Wittig olefination

OH OH
BnO

OH

NBDHN

O

HO

OH
OH

7

Moving forward the synthesis will be altered on opening the second epoxide
using a more traditional anti-opening using a Lewis acid and nucleophile. Following
reactions are expected to yield similar results to previous attempts before arriving at
4. Ozonolysis should proceed smoothly to cleave double bond and sequential
carbonyl reduction using NaBH4 to generate a primary alcohol. Primary alcohol will
be tosylated using Tosyl chloride (TsCl) before undergoing intercellular cyclization.
After generation of locked pyranose, the synthetic steps can be easily modified to
generate altering stereochemistry through Sharpless asymmetric epoxidation to test
the effect of altering stereocenters.
This synthesis can be easily altered to generate furanose locked analogs by
simply stopping after secondary SAE and cyclizing. This will be explored in the future
as both furanose and pyranose probes are developed to further understand the
importance of sugar ring size in fructose transport.
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Scheme 3.2: Synthesis of locked furanose probe

3.3 Conclusions
Initial groundwork has been developed for a series of probes designed to
effectively determine stereocenter and ring size importance in fructose transport.
With synthetic optimizations, these probes should be able to be made on milligram
scale and carried over for cellular studies.
3.4 Experimental
All reactions (unless otherwise stated) were done with flame dried glassware
and using commercially available reagents without further purification from SigmaAldrich. Silica gel was purchased from Siliflash and has a size of 43-63 µm. Solvents
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used were taken from dried source. Column chromatography was performed using
SiliCycle silica gel (230-400 mesh). Thin layer chromatography (TLC) was performed
using Sigma-Aldrich TLC plates over aluminum support 200um thickness with 25 µm
particle size. Structural analysis of compounds was carried out with 400 MHz Varian
NMR instrument. Spectra are reported in parts per million (ppm) relative to the
solvent resonances (δ), with coupling constants (J) in Hertz (Hz).
Benzyl Protection of alkyne
HO

BnO

BnBr (1 eq)
OH

rt, H2O, KOH (4eq)

OH

84%

1

1,4-butynediol (20 g, 232 mmol, 4 eq) was dissolved in 200 mL of deionized
water at room temperature and allowed to stir until dissolved. After starting material
was dissolved potassium hydroxide (13 g, 232 mmol, 4 eq) was added and allowed
to stand for 30 min. After 30min benzyl bromide was added dropwise and allowed to
stir overnight. Solution was then extracted with 3 treatments of 75 mL of diethyl ether
and dried over sodium sulfate. Solvent was removed under reduced pressure to
leave the yellow crude oil (9.2g) and was then purified over silica gel using ethyl
acetate/hexane (10/90)solvent system to yield 1 in 84% yield[3]. 1H-NMR CDCl3: δ
7.2 (m, 5H), 4.80 (s, 2H), 3.80 (d, 2H), 3.90 (d, 2H), 2.8 (s, b, 1H).
Reduction of alkyne to trans-alkene.
Red-Al

BnO
OH

0 C to rt, THF
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BnO

OH

Alkyne 1 (9 g, 50.3 mmol) dissolved in 100 mL of dry THF and cooled to 0 Co
under Ar atmosphere. Red-Al (60% toluene, 30 g, 87 mmol) was then added
dropwise over a course of 10 min via syringe. Reaction allowed to stand for 1 hour at
room temperature. Reaction was cooled to 0 Co and 100 mL of 10% sulfuric acid was
added to quench reaction. The resulting biphasic system was extracted with three
times with 75 mL of dichloromethane. Solvent was removed under reduced pressure
to give very light yellow oil (7.8 g) and then purified over silica gel using ethyl
acetate/hexane (10/90) solvent system to yield 2 in 72% yield [4]. 1H-NMR CDCl3: δ
7.1 (m, 5H), 5.9 (m, 2H), 4.7 (s, 2H), 4.1 (d, 2H), 4.0 (d, 2H), 2.8 (b, 1H)
Sharpless asymmetric epoxidation (SAE)

BnO

OH

T-BuOOH (4eq)
-23 C 24h, DCM

O
BnO

OH

Dried molecular sieves 4Å (4.0 g) were added to dry dichloromethane in a
flame dried flask at -23 Co before both titanium tetra(isopropoxide) (0.25 eq) and (-)
diethyl tartrate (0.36 eq) are added to solvent under Ar atmosphere. Dried tert-butyl
hydroperoxide 3.5M solution in toluene (4eq) was added dropwise over 20min before
allowing solution to stand with stirring for 30 min. After allotted time allylic alcohol (1
eq) was dissolved in of dried dichloromethane and added to solution dropwise over
1hr. Reaction was kept at -20 C° overnight before being warmed to room
temperature and quenched with 30% NaOH solution in water and stirred for 20 min.
The molecular sieves were, and salts were then filtered off using vacuum filtration
before the two phases were separated. Aqueous phase was extracted with three
washes of 75 mL of dichloromethane. Resulting organic phase was dried over
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sodium sulfate and concentrated under reduced pressure, followed by purification
using column chromatograph (silica gel, 10/90 EtOAc-hexane). Resulting in epoxide
in 78% yield [5]. 1H-NMR CDCl3: δ 7.2 (m, 5H), 4.6 (dd, 2H), 3.9 (m, 1H), 3.7 (dd,
1H), 3.5 (m, 1H), 3.4 (dd, 1H), 3.2 (m, 1H), 2.9 (b, 1H)
Parikh-Doering oxidation of 3
O
BnO

OH

SO3*py, DMSO
TEA, 0 C to rt, 1h, DCM

O
BnO

O

To a dried flask dichloromethane (4.3 mL/mmol) and dimethylsulfoxide (0.73
mL/mmol) were cooled to 0 C° before epoxy alcohol was added to solution with
stirring under Ar atmosphere. To this solution, TEA (3 eq) was added via syringe,
and sulfur trioxide pyridine complex (4 eq) purchased from TCI was added rapidly.
Solution turns from clear to a light brown/red and is allowed to come to room
temperature. After 2 h, reaction was monitored by TLC before being cooled back
down to 0 C°. Reaction is quenched by a saturated solution of copper sulfate
pentahydrate and extracted with dichloromethane. Organic phase was dried over
sodium sulfate and concentrated under reduced pressure before being purified by
column chromatography (silica gel, 30/70 EtOAc-hexane). Aldehyde was purified to
give 53% yield [6]. 1H-NMR CDCl3: δ 10.4 (d, 1H), 7.2 (m, 5H), 4.6 (dd, 2H), 3.9 (m,
1H), 3.7 (dd, 1H), 3.5 (m, 1H), 3.4 (dd, 1H), 3.2 (m, 1H)

56

3.5 Additional Information

OH
Figure 3.1 H1 NMR at 400Hz for BnO
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OH
Figure 3.2 C13 NMR at 400Hz for BnO
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Figure 3.3 H1 NMR at 400 Hz for BnO

OH
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Figure 3.4: C13 at 400Hz for BnO

OH
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O

OH

Figure 3.5: H1 NMR at 400Hz for BnO
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Figure 3.6 C13 at 400Hz for BnO
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Figure 3.7:
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Figure 3.8:
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at 400Hz for BnO

O
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Chapter 4
Future Work

Although current probes have given insight into transporter-substrate tolerance, gaps
remain. ManCou probe’s C4 position has the ability for many more functional groups to be
added to give further insight into importance of the electron density of the aromatic system as
well as how bulky hydrophobic/hydrophilic substitutions may affect uptake. Coumarin
functionalization can also affect the color of emission and, if used to target different GLUTs,
may allows for simultaneously tracking of the activity of different GLUTs.

4.1 Finish Synthesis of Furanose/Pyranose Probes
With the completion of the ManCou1,2 and 3, strides have been made in
understanding substrate and payload tolerance. However how exactly GLUT2 or GLUT5
differentiate between sugar substrates, if they do at all, remains unclear. In Chapter 2 initial
work has been done in an attempt to construct a multitude of probes in an attempt to
determine this mechanism. Once probe synthesis is completed using a multitude of cellular
lines shown to express GLUT5, GLUT2 and neither will need to be exposed to the probes.
From their fluorescent uptake or lack thereof, should help determine the substrates specific
toward each transporter.
4.2 Develop more ManCou Probes
Current ManCou probes have given interesting insight on transport and
transporter/substrate tolerance. However there is significant room for expansion. There are
several other amino or hydroxyl coumarins commercially available with differing functional
groups that can give insight in hydrophobic tolerance, sterics, sugar-fluorophore linker role,
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etc. Manipulating the C4 functional group can also influence the color of the probe as well
from violet all the way to red. These probes can shed even more light on the confusing topic
of substrate tolerance.
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Figure 4.1: Potential future probes

4.3 Multicolor Assay to Measure GLUT Activity
With the construction of ManCou probes and the already tested NBD probes, it is
now possible to develop a multicolor assay to measure various GLUT activity simultaneously.
Using multiple colors, it will be possible to track the activity of various transporters in real time
and potentially diagnose cancer types very quickly and being able to avoid long gene
sequencing experiments.
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